Navigation Links
Amyloid Beta Level in Serum Predicts Risk for Vascular Disease in First-Degree Relatives of Alzheimer's Patients
Date:2/6/2009

People with a family history of Alzheimer’s disease, who have high levels of amyloid beta (A) in the serum, are at increased risk for vascular disease.

Manhasset, NY (Vocus) February 6, 2009 -- People with a family history of Alzheimer’s disease, who have high levels of amyloid beta (A²) in the serum, are at increased risk for vascular disease. These heightened A² levels may predict whether those without symptoms may progress towards dementia in years to come.

Michael Mullan, MD, and his colleagues at the Roskamp Institute in Sarasota, Fl., collaborated with statisticians at the London School of Hygiene and Tropical Medicine to see if elevated levels of A² in the blood in first-degree relatives of Alzheimer’s patients are associated with risk factors for vascular disease. Recent studies have shown that vascular disease is a major risk factor for Alzheimer’s. They recruited 197 local study subjects from the Alzheimer’s Disease Anti-Inflammatory Prevention Trial, which included unaffected family members, as well as 98 community elders in Florida. They studied the association of amyloid beta levels in serum with risk factors for vascular disease, including total cholesterol, LDL, HDL, systolic blood pressure, diastolic blood pressure and serum creatinine. They also looked at medications prescribed for vascular disease or the risk factors associated with vascular disease.

A² in serum is used as a marker to predict A² accumulation in the brain, which is one of the key pathologies of Alzheimer’s. In this study, the scientists found A² levels were significantly higher in first-degree relatives of Alzheimer’s patients, as compared with the elder community controls. The scientists say they suspect this elevation may be “indicative of increased amyloid beta production due to genetic and/or other risk factors.”

“These findings suggest that an increased risk of Alzheimer’s disease associated with family history may be mediated in part through the enrichment of individuals with vascular risk factors and may be reflective of pre-symptomatic Alzheimer’s disease pathology,” Dr. Mullan and his colleagues wrote.

In another stunning finding in the same issue of Molecular Medicine, scientists from Virginia Commonwealth University, Northwestern University, UCSF, UCLA, University of Pennsylvania, and University of North Carolina, identified a genetic signature for a hepatitis C virus-induced liver cancer, and different genetic handprints for cirrhosis caused by hepatitis C. They were able to use these genetic signatures to distinguish between pathological stages of liver cancer and early disease states, suggesting a way to diagnose this hepatocellular carcinoma earlier in the disease process.

Molecular Medicine is published by The Feinstein Institute for Medical Research, part of the North Shore-LIJ Health System. For more information on the study, visit www.molmed.org or contact Veronica J. Davis. Free podcasts from the latest issue of Molecular Medicine are also available on the journal’s web site and in iTunes.

###

Read the full story at http://www.prweb.com/releases/2009/02/prweb1966994.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis
2. Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis
3. MSU study finds high level of medical mistrust among minority women impacts quality of health care
4. Ther-Rx Corporation Issues Voluntary Nationwide Recall of Prescription Prenatal and Iron Supplements to Wholesale Level
5. ETHEX Corporation Issues Voluntary Nationwide Recall of Prescription Prenatal and Iron Supplements to Wholesale Level
6. New Web-Based User Self Service & Identity Management Software for Active Directory takes Security, User Convenience to a Whole New Level
7. Mammography utilization in the United States decreases: A state-level look
8. HPV18 DNA levels are not prognostic for precancerous cervical lesions
9. Cleveland Clinic and Mubadala Healthcare Name CEO of Cleveland Clinic Abu Dhabi
10. New Study: Higher DHA Levels Improve Neurodevelopmental Outcomes in Premature Girls
11. Children with inflammatory bowel disease have surprisingly high folate levels, study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Conditions were ideal for Global Lyme Alliance’s (GLA) ... with sunny skies, a light breeze and temperatures in the 60s. Over 400 runners, ... Run and Walk and 1-mile walk were held to increase awareness about Lyme ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... reveals that infants born with severe congenital diaphragmatic hernia have better survival rates ... with congenital diaphragmatic hernia (CDH)—a condition where the diaphragm fails to form completely, ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... team BioCellection won the $30,000 Perlman Grand Prize of the 2016 Wharton Business ... Award, the Michelson People’s Choice Award, and the Committee Award for Most ‘Wow ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... of patented products, announces the Gyrociser, an exercise invention which aids in proper ... billion," says Scott Cooper, CEO and Creative Director of World Patent Marketing. "Globalization ...
(Date:4/29/2016)... ... April 29, 2016 , ... Melanoma is the deadliest type of skin cancer. Although only about ... of skin cancer deaths. More than 10,000 people are expected to die of melanoma this ... it is the one of the most commonly diagnosed cancers in young women. A recent ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... Research and Markets has announced the addition ... report to their offering.      (Logo: ... plastic surgery products market is expected to grow at ... ,The growing adoption of laser in aesthetics is another ... Lasers are used to treat a broad range of ...
(Date:4/28/2016)... Dr. ... und Stephen Schmidt werden Teil ... ein führender Anbieter cloudbasierter Softwarelösungen für den ... neue Führungskräfte zum Team Sicherheit und Pharmakovigilanz ... Erfahrungen mitbringen.  Dies wird die Geschäftseinheit Sicherheit ...
(Date:4/28/2016)... YORK , April 28, 2016 ... online consumer insights on healthcare, announced today that it ... their report Cool Vendor in Life Sciences, 2016, ... April 15, 2016.  The report focuses on life-science- oriented ... gain insight from patients and doctors, confirm medication ingestion, ...
Breaking Medicine Technology: